Oncolytics Biotech Inc. (ONCY)

$1.34

+0.03 (+2.29%)
Rating:
Recommendation:
-
Symbol ONCY
Price $1.34
Beta 1.733
Volume Avg. 0.12M
Market Cap 77.439M
Shares () -
52 Week Range 0.8-2.38
1y Target Est -
DCF Unlevered ONCY DCF ->
DCF Levered ONCY LDCF ->
ROE -66.49% Strong Sell
ROA -59.96% Strong Sell
Operating Margin -
Debt / Equity 26.93% Neutral
P/E -
P/B 2.73 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ONCY news


Dr. Matthew Coffey
Healthcare
Biotechnology
NASDAQ Capital Market

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.